A Randomized, Placebo-Controlled, Double-Blind Phase III Study of the Effect of First-Line Treatment With Intercalated Tarceva Versus Placebo in Combination With Gemcitabine/Platinum on Progression-Free Survival in Patients With Stage IIIB/IV Non-Small Cell Lung Cancer

Trial Profile

A Randomized, Placebo-Controlled, Double-Blind Phase III Study of the Effect of First-Line Treatment With Intercalated Tarceva Versus Placebo in Combination With Gemcitabine/Platinum on Progression-Free Survival in Patients With Stage IIIB/IV Non-Small Cell Lung Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jan 2016

At a glance

  • Drugs Erlotinib (Primary) ; Carboplatin; Cisplatin; Gemcitabine
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms FASTACT-2; FASTACT-II
  • Sponsors Roche
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Jan 2016 Results of pooled analysis of seven studies published in the Journal of Thoracic Oncology
    • 26 Jan 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top